Abbott Labs (ABT) Announces XIENCE(TM) Drug Eluting Stent Outperforms Market-Leading Stents

May 13, 2008 12:51 PM EDT

Abbott Laboratories (NYSE: ABT) today announced that trials on Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent System demonstrated that XIENCE V continues to deliver clinically superior benefits for patients compared to the TAXUS(R) paclitaxel-eluting coronary stent system.

In this trial of more than 1,000 patients, XIENCE V demonstrated a 45 percent reduction in the risk of major adverse cardiac events and a 32 percent reduction in the risk of target vessel failure at two years as compared to TAXUS.

Abbott's VP of Medical Products, Dr. John Capek, said, "From these results, it is clear that XIENCE V can deliver sustained benefits to patients over the long term. We continue to be pleased with the way XIENCE V is performing, with outstanding results that are consistent with what we have seen throughout the SPIRIT III trial."

Abbott Laboratories engages in the development, manufacture, and sale of health care products worldwide. [BCS]

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?